Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

12.39USD
22 Sep 2017
Change (% chg)

$-0.42 (-3.28%)
Prev Close
$12.81
Open
$12.76
Day's High
$12.76
Day's Low
$12.36
Volume
173,397
Avg. Vol
253,659
52-wk High
$19.50
52-wk Low
$11.81

Latest Key Developments (Source: Significant Developments)

Lexicon Pharmaceuticals gets European Commission's approval for Xermelo
Tuesday, 19 Sep 2017 12:34pm EDT 

Sept 19 (Reuters) - Lexicon Pharmaceuticals Inc ::European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy.Says ‍approval allows for marketing of Xermelo by co's collaborator Ipsen in all 28 member states of EU, Norway and Iceland​.  Full Article

Lexicon Pharma reports positive pooled continuous glucose monitoring data
Friday, 8 Sep 2017 07:00am EDT 

Sept 8 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin.Lexicon Pharmaceuticals Inc - ‍results were statistically significant and clinically meaningful for both doses of sotagliflozin in study​.  Full Article

Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin
Tuesday, 15 Aug 2017 07:00am EDT 

Aug 15 (Reuters) - Lexicon Pharmaceuticals Inc :Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin.Achievement of intandem2 secondary endpoints replicates intandem1 results​.Sotagliflozin was generally well tolerated during 28-week extension period​.New data showed a1c benefit sustained over 52 weeks, achievement of all secondary endpoints for both sotagliflozin doses​.  Full Article

Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes
Monday, 31 Jul 2017 06:01pm EDT 

July 31 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes.Lexicon Pharmaceuticals - says ‍Sanofi intends to file applications in first half of 2018 for EU and U.S. Regulatory reviews of sotagliflozin​.Lexicon Pharmaceuticals- ‍opt-in decision based on positive data from 3 phase 3 studies, intandem1, intandem2, intandem3​.  Full Article

Lexicon Pharmaceuticals amends collaboration and license agreement
Friday, 7 Jul 2017 09:34am EDT 

July 7 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH.Lexicon Pharmaceuticals Inc - remain eligible to receive an aggregate of $210 million upon achievement of amended clinical development milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $220 million upon achievement of specified regulatory milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $990 million upon the achievement of specified commercial milestones.Lexicon Pharmaceuticals - under amended milestones, eligible to receive up to $110 million upon achievement of 4 milestones.Lexicon Pharma-pursuant to amendment, co eligible to $100 million upon achievement of milestone based on results of studies in type 2 diabetes patients.  Full Article

Lexicon Pharmac reports positive late-stage data on diabetes drug
Friday, 9 Jun 2017 07:01am EDT 

June 9 (Reuters) - Lexicon Pharmaceuticals Inc -:Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes.Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes.Lexicon Pharmaceuticals Inc - ‍study met its primary endpoint​.Sotagliflozin demonstrated a generally well tolerated safety profile during a 24-week treatment period.Lexicon Pharmaceuticals Inc - sotagliflozin demonstrates statistically significant benefit in primary endpoint.Lexicon Pharmaceuticals Inc - results support a unique drug profile as an sglt1 and sglt2 inhibitor.  Full Article

Lexicon Pharmaceuticals reports Q1 revenue $18.3 million
Tuesday, 2 May 2017 04:44pm EDT 

May 2 (Reuters) - Lexicon Pharmaceuticals Inc :Lexicon Pharmaceuticals reports first quarter 2017 financial results and provides a business update.Q1 loss per share $0.33.Q1 revenue $18.3 million versus I/B/E/S view $17.7 million.Q1 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Lexicon Pharmaceuticals - Expects current liquidity, capital resources, expected revenues, will be sufficient to fund operations at least through 2018.  Full Article

Lexicon Pharma files for offering of up to $10.1 mln by selling stockholders - SEC filing
Monday, 20 Mar 2017 10:34am EDT 

Lexicon Pharmaceuticals Inc :Files for secondary offering of up to $10.1 million by selling stockholders - SEC filing.  Full Article

Lexicon Pharmaceuticals reports Q4 loss per share $0.31
Friday, 3 Mar 2017 07:00am EST 

Lexicon Pharmaceuticals Inc : Lexicon Pharmaceuticals provides clinical pipeline update and reports 2016 fourth quarter and full year financial results . Q4 revenue $23 million versus $127.3 million . Q4 revenue view $15.6 million -- Thomson Reuters I/B/E/S . Q4 loss per share $0.31 .Q4 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Lexicon reports top-line results from phase 2 clinical trial conducted in collaboration with JDRF
Monday, 5 Dec 2016 04:01pm EST 

Lexicon Pharmaceuticals Inc : Lexicon reports top-line results from phase 2 clinical trial conducted in collaboration with JDRF . Lexicon Pharmaceuticals-sotagliflozin was well tolerated in study, smaller proportion of patients experiencing treatment-emergent adverse events . Results for a1c primary endpoint numerically favored sotagliflozin, but did not reach statistical significance .Lexicon Pharmaceuticals-patients treated with sotagliflozin achieved mean reduction of 0.62 kg in body weight from baseline to week 12, compared to placebo.  Full Article

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy